Innovative Medicine
-
New STELARA® Data Show Inhibition Of Joint Destruction In Patients With Active Psoriatic Arthritis
Integrated Analysis of Two Pivotal Phase 3 Studies Showed STELARA Inhibited the Progression of Structural Damage at Week 24, and Demonstrated Continued Inhibition through Two Years -
-
-
-
-
-
New Study Shows Circulating Tumor Cell Enumeration – as Part of Composite Biomarker Panel –May Serve as a Surrogate for Efficacy Response in Metastatic Castration-Resistant Prostate Cancer
First study to find patients with unfavorable risk profile at 12 weeks have worse prognosis and should be considered for alternative treatments -
Japanese Health Authority Approves SOVRIAD™ For The Treatment Of Genotype-1 Chronic HCV Infection
Japan is the first country in the world where SOVRIAD™ is approved -